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Long-term virological outcome in children on
antiretroviral therapy in the UK and Ireland
Trinh Duonga, Ali Judda, Intira Jeannie Collinsa, Katja Doerholtb,
Hermione Lyallc, Caroline Fosterc, Karina Butlerd, Pat Tookeye,
Delane Shingadiaf, Esse Mensong, David T. Dunna, Di M. Gibba,
on behalf of the Collaborative HIV Paediatric Study
Steering Committee
Objective: To assess factors at the start of antiretroviral therapy (ART) associated with
long-term virological response in children.
Design: Multicentre national cohort.
Methods: Factors associated with viral load below 400 copies/ml by 12 months and
virologic failure among children starting 3/4-drug ART in the UK/Irish Collaborative HIV
Paediatric Study were assessed using Poisson models.
Results: Nine hundred and ninety-seven children started ART at a median age of
7.7 years (inter-quartile range 2.9–11.7), 251 (25%) below 3 years: 411 (41%) with
efavirenz and two nucleoside reverse transcriptase inhibitors (EFVþ2NRTIs), 264
(26%) with nevirapine and two NRTIs (NVPþ2NRTIs), 119 (12%; 106 NVP, 13
EFV) with non-nucleoside reverse transcriptase inhibitor and three NRTIs
(NNRTIþ3NRTIs), and 203 (20%) with boosted protease inhibitor-based regimens.
Median follow-up after ART initiation was 5.7 (3.0–8.8) years. Viral load was less than
400 copies/ml by 12 months in 92% [95% confidence interval (CI) 91–94%] of the
children. Time to suppression was similar across regimens (P¼0.10), but faster over
calendar time, with older age and lower baseline viral load. Three hundred and thirty-
nine (34%) children experienced virological failure. Although progression to failure
varied by regimen (P<0.001) and was fastest for NVPþ2NRTIs regimens, risk after
2 years on therapy was similar for EFVþ2NRTIs and NVPþ2NRTIs, and lowest for
NNRTIþ3NRTIs regimens (P-interaction¼0.03). Older age, earlier calendar periods
and maternal ART exposure were associated with increased failure risk. Early treatment
discontinuation for toxicity occurred more frequently for NVP-based regimens, but
5-year cumulative incidence was similar: 6.1% (95% CI 3.9–8.9%) NVP, 8.3% (95% CI
5.6–11.6) EFV, and 9.8% (95% CI 5.7–15.3%) protease inhibitor-based regimens
(P¼0.48).
Conclusion: Viral load suppression by 12 months was high with all regimens.
NVPþ3NRTIs regimens were particularly efficacious in the longer term and may be
a good alternative to protease inhibitor-based ART in young children.
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Introduction
Maintenance of long-term viral suppression is a particular
challenge for HIV-infected children who will likely
require antiretroviral therapy (ART) for life, and the
foundations of treatment success depend on the effec-
tiveness of first-line regimens [1,2]. A recent European
study found risk of triple-class viral load failure was twice
as high in children compared to adults [3]. WHO 2013
guidelines recommend lopinavir/ritonavir (LPV/r)-
based regimens as the preferred choice for first-line
therapy in children aged under 3 years and efavirenz
(EFV)-based regimens for 3 years and over; nevirapine
(NVP)-based regimens are recommended as an alterna-
tive and have the advantage of being available as paediatric
fixed-dose combination in most resource-limited settings
[4].
Four clinical trials have evaluated first-line ART strategies
in children. The International Maternal Pediatric
Adolescent AIDS Clinical Trials (IMPAACT) 1060 trial
cohorts 1 and 2 included mainly African children, all aged
below 3 years, with and without NVP exposure for
prevention of mother-to-child transmission (pMTCT),
respectively [5,6]. Both cohorts reported higher rates of
treatment failure (composite endpoint of death, virolo-
gical failure and regimen-limiting toxicity) in the NVP
versus LPV/r-based ART group at 24 weeks, suggesting
short-term benefit of LPV/r irrespective of prior NVP
exposure for pMTCT. In contrast, the PENPACT-1
[Paediatric European Network for Treatment of AIDS
(PENTA) and Pediatric AIDS Clinical Trials Group
(PACTG/IMPAACT)] trial with median 5 years follow-
up found similar viral load, CD4þ, and clinical outcomes
among children initiating protease inhibitor compared
with non-nucleoside reverse transcriptase inhibitor
(NNRTI)-based regimens [7]. However, PENPACT-1
enrolled only 26% children aged below 3 years and
included EFV and NVP as the NNRTI, and LPV/r and
nelfinavir as the protease inhibitor, although virological
suppression was similar across initial protease inhibitors
and NNRTIs, Finally, the Antiretroviral research for
Watoto (ARROW) trial in Uganda and Zimbabwe
reported early viral load and CD4þ benefit from four-
drug ART induction with NNRTIþ 3NRTIs, which
was not sustained after stopping the fourth drug at
36 weeks [8]. The NNRTI (NVP or EFV) was chosen by
clinicians according to local availability and age, with over
a third of the children receiving EFV which was similar
across treatment arms. Nearly a third of the children
were below 3 years of age, and they had similar rates of
viral load suppression less than 400 copies/ml to older
children.
Response to different first-line regimens has also been
reported from paediatric observational studies. In the
European Pregnancy and Paediatric HIV Cohort
Collaboration (EPPICC) infant cohort, four-drug
NNRTI-based regimens had better 12-month virological
and immunological response than other regimens [9]. In
several studies from sub-Saharan Africa, longer time to
virological failure was observed for EFV versus NVP-
based initial ART, consistent with a recent meta-analysis
showing superior virologic response for EFV to NVP in
both randomized controlled trials and observation studies
in adults [10–14]. In addition, randomized trials in adults
have shown EFV to have either similar or better efficacy
compared to protease inhibitors [15–18].
Further long-term data across all ages in children are
therefore required to compare effectiveness of the first-
line regimens. We assessed factors associated with
virological suppression within 12 months of ART
initiation and also virological failure during follow-up
among children in the national UK/Ireland Collaborative
HIV Paediatric Study (CHIPS), focusing particularly on
first-line regimens. Since drug-related adverse events
can lead to poorer adherence and regimen changes,
complicating clinical management, we also examined
drug discontinuation for toxicity by regimen.
Methods
Details of CHIPS were previously described [19]. Briefly,
infants born to HIV-infected women and children
presenting in the UK/Ireland with HIV are reported
to the National Study of HIV in Pregnancy and
Childhood. Follow-up data for HIV-infected children
are then collected through CHIPS. Both studies have
NHS Research Ethics approval.
Analyses included antiretroviral-naı¨ve children aged
below 18 years enrolled up to November 2013, who
started ART from 1997 with at least three drugs
(excluding unboosted-protease inhibitor or triple NRTI
regimens, and ART for neonatal prophylaxis), and had at
least one viral load measurement within 12 months
of initiation.
Statistical methods
Date of virological suppression on ARTwas estimated as
the mid-point between the last viral load measurement
above 400 copies/ml before suppression (or ART start
date if not available) and the first viral load measurement
below 400 copies/ml. Time from starting ART to
virological suppression by 12 months was analysed with
follow-up censored at the earliest of the following: date
of initial suppression, last viral load measurement, and
12 months from initiation.
The definition of virological failure, adapted from a
previous study, was the earliest of the following:
confirmed rebound above 400 copies/ml (the second
of the two consecutive measurements >400 copies/ml
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within 6 months) after previous suppression; uncon-
firmed rebound above 400 copies/ml followed by
changing of at least two drugs within 6 months (to
allow the possibility of the clinician regarding the child to
have failed treatment and therefore switched before
confirmed rebound, leading to re-suppression); or viral
load above 400 copies/ml after 12 months without
previous suppression [20]. Censoring for time to
virological failure was at the earliest of the following:
date of virological failure, last viral load measurement, and
the first viral load measurement without a subsequent
measurement within 12 months (to allow occasional long
gaps between clinic visits). The cumulative proportion of
children experiencing each outcome over time from
ART initiation was estimated using Kaplan–Meier
methods.
Predictors of each virological outcome were assessed
using Poisson mixed models, accounting for within-clinic
clustering. Analyses ignored treatment changes and
interruptions. The effect of covariates were estimated
adjusting for time from ART initiation, a priori
confounders and all covariates with a P value less than
0.05 in the multivariable models. A priori confounders
were age, calendar year, first-line regimen, and also for
the comparison of regimen, baseline viral load, CD4%
and pre-treatment AIDS diagnosis. Other potential
predictors were sex, ethnicity, born in UK/Ireland or
abroad, exposure to maternal ART during pregnancy or
at delivery, and weight-for-age z-score [21]. Due to the
small number of children on EFVþ 3NRTIs regimens,
they were combined with those on NVPþ 3NRTIs
in analyses.
The effect of the regimen was compared for all children
combined, and by age under and over 3 years, by including
an interaction (as EFV was not recommended in <3 years
until May 2013) [4,22]. Also, interaction between regimen
and time since ART initiation (<24 and24 months) was
assessed in the analysis of virological failure.
The following sensitivity analyses were performed:
adjusting additionally for NRTI backbones in analyses
of 3-drug regimens only; viral load limits of above 1000
and above 5000 copies for rebound in the definition of
virological failure, with virologic suppression defined as
below 400 copies/ml; restricting analyses to children born
in the UK/Ireland without known exposure to maternal
NNRTI-based ART, since maternal ARTexposure may
be under-reported among children born abroad [23];
excluding children ever on once-daily NVP during
maintenance dose as twice-daily dosing is currently
recommended; and in the analysis of virological failure,
follow-up censored at treatment interruption with viral
load below 400 copies/ml to exclude viral rebound while
off treatment. Missing data for covariates were imputed
using Multivariate Imputation by Chained Equations
based on 20 cycles [24].
Finally, the cumulative incidence of treatment discon-
tinuation (stopping the initial protease inhibitor or
NNRTI drug) for toxicity was estimated by regimen
using competing risk methods, with discontinuation for
other reasons considered a competing event [25].
Statistical analyses were performed using Stata version 12
(Stata Corporation, College Station, Texas, USA).
Results
Of the 997 children included in this analysis, 97% were
perinatally infected, half were female, 82% were of black
African ethnic origin, and 42% were born in the UK/
Ireland (Table 1). Sixty-eight (7%) were exposed to
maternal ART during pregnancy or delivery, of whom
27 were treated with NNRTI-based regimens (including
fourwith single-doseNVP).Median age at ART initiation
was 7.7 [inter-quartile range (IQR) 2.9–11.7] years, with
251 (25%) below 3 years of age. Median baseline CD4%
was 15% (9–20%). One-fifth of the children had a pre-
treatment AIDS-defining diagnosis. Median follow-up
after initiation was 5.7 (3.0–8.8) years.
First-line regimen
Types of first-line regimen varied with age and calendar
period (Fig. 1). Over three-quarters of the children
aged below 3 years were initiated on NVPþ 2NRTIs
(41%, 104/251) or 3NRTIs (37%, 93/251). Among those
aged at least 3 years, 54% (404/746) received EFVþ 2NR-
2NRTIs regimens. In this age group, use of NVPþ
2NRTIs regimens decreased over time and NNRTIþ
3NRTIs regimens were infrequently prescribed (4%,
n¼ 26; 13 NVP, 13 EFV). Use of boosted protease
inhibitor regimens commenced in 2000 and increased to
36% from 2008 onwards, with similar trends across age
groups. LPV/r accounted for nearly 90% of the protease
inhibitor regimens prescribed (177/203), with the
remaining children on atazanavir (8%, 16/203) or
darunavir (5%, 10/203). Eight percent (16/203) of the
children on protease inhibitor regimens received three
NRTIs. Eighty-nine percent (106/119) of the children in
the NNRTIþ 3NRTIs group received NVP and 11%
(13/119) EFV.
The choice of NRTI backbone differed by regimen
(Table 1). Among the children on three-drug regimens,
abacavirþ lamivudine and tenofovirþ emtricitabine were
more frequently used with EFV and protease inhibitor-
based regimens, and zidovudineþ lamivudine and dida-
nosineþ stavudine with NVP-based regimens, reflecting
ART availability over calendar periods. Nearly all child-
ren on four-drug regimens received zidovudineþ
lamivudineþ abacavir.
Compared to those on other regimens, children on
NNRTIþ 3NRTIs regimens were younger, had lower
Virological outcomes in children with HIV Duong et al. 2397
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baseline CD4% (accounting for age), higher viral load and
higher proportion with pre-treatment AIDS diagnoses
(Table 1). Median time on four drugs before dropping
down to three drugs was 21.4 (13.1–36.2) months.
Virological suppression by 12 months
An estimated 92% [95% confidence interval (CI)
91–94%] of the children had viral load suppressed below
400 copies/ml within 12 months; the corresponding
proportion was 96% (94–97%) among those starting
ART since 2005. Kaplan–Meir curves of time to
suppression by regimen and age are shown in Fig. 2a.
In the multivariable analysis, time to suppression was
similar by regimen (global P¼ 0.10; Table 2), which was
observed for both age below 3 years and at least 3 years
(P-interaction¼ 0.80, data not shown). Time to suppres-
sion improved with later calendar years, older age and
lower baseline viral load.
Results were similar in sensitivity analyses which included
only children starting ART since 2005 (n¼ 572), were
restricted to children born in the UK/Ireland without
maternal NNRTI-based ARTexposure, and adjusted for
NRTI backbones (data not shown).
Virological failure
Three hundred and thirty-nine (34%) of the 997 children
experienced virological failure during follow-up: 268
(79% of 339) had confirmed rebound above 400 copies/
ml; 13 (4%) had unconfirmed rebound followed
by a change of at least two drugs within 6 months;
and 58 (17%) had viral load above 400 copies/ml after
12 months without having previously suppressed.
The estimated proportion experiencing virological
failure by 2 and 5 years was 23.6% (95% CI 20.9–
26.6%) and 39.4% (95% CI 35.8–43.2%), respectively.
The Kaplan–Meier curves of time to virological failure
are shown in Fig. 2b.
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Table 1. Characteristics at antiretroviral therapy initiation, by type of first-line antiretroviral therapy regimen (nU997).
Type of first-line ART regimen
NVPþ2NRTIs EFVþ2NRTIs Boosted PI NNRTIþ3NRTIs Overall
Number (%) or median [IQR]
Number of children 264 411 203a 119 [106 NVP, 13 EFV] 997
Perinatal infection 253 (97) 379 (96) 193 (99) 117 (99) 942 (97)
Female sex 136 (52) 218 (53) 115 (57) 61 (51) 530 (53)
Ethnic group
White 22 (9) 11 (3) 15 (8) 9 (8) 57 (6)
Black African 212 (81) 352 (87) 158 (79) 86 (72) 808 (82)
Other 27 (10) 41 (10) 26 (13) 24 (20) 118 (12)
Born in the UK/Ireland 134 (51) 108 (27) 86 (43) 90 (76) 418 (42)
Maternal ART in pregnancy or during labour
None 236 (89) 407 (99) 186 (92) 100 (84) 929 (93)
Single-dose NVP 3 (1) 0 (0) 1 (0.5) 0 (0) 4 (0.5)
Other NNRTI-based ART 7 (3) 2 (0.5) 7 (3) 7 (6) 23 (2)b
Other ART 18 (7) 2 (0.5) 10 (5) 12 (10) 42 (4)
Age (years) 4.1 [1.6–8.8] 10.4 [6.8–12.9] 9.3 [3.4–13.0] 0.6 [0.3–2.4] 7.7 [2.9–11.7]
<3 years 104 (39) 7 (2) 47 (23) 93 (78) 251 (25)
Calendar period
Before 2002 89 (34) 33 (8) 3 (1) 28 (24) 153 (15)
2002–2004 74 (28) 103 (25) 49 (24) 46 (39) 272 (27)
2005–2007 63 (24) 129 (31) 39 (19) 27 (23) 258 (26)
2008–2013 38 (14) 146 (36) 112 (55) 18 (15) 314 (31)
Viral load (log10c/ml) 5.0 [4.4–5.5] 4.9 [4.3–5.2] 4.9 [4.1–5.3] 5.7 [5.2–5.9] 5.0 [4.3–5.5]
CD4þ per cent 17 [11–23] 13 [8–18] 16 [11–21] 16 [8–28] 15 [9–20]
Pre-treatment AIDS 34 (13) 55 (13) 39 (19) 58 (49) 186 (19)
NRTI backbone
In three-drug regimens
ABC 3TC 77 (29) 255 (62) 111 (59) – 443 (51)
ZDV 3TC 114 (43) 63 (15) 37 (20) – 214 (25)
d4T 3TC 24 (9) 19 (5) 6 (3) – 49 (6)
DDI d4T 44 (17) 7 (2) 4 (2) – 55 (6)
TDF FTC 2 (1) 57 (14) 20 (11) – 79 (9)
Other 3 (1) 10 (2) 9 (5) – 22 (3)
In four-drug regimens
ZDV 3TC ABC – – 16 (100) 116 (98) 132 (98)
Other – – 0 (0) 3 (2) 3 (2)
3TC, lamivudine; ABC, abacavir; d4T, stavudine; ddI, didanosine; FTC, emtricitabine; TDF, tenofovir; ZDV, zidovudine. Number of children with
missing data: mode of infection, 30; sex, 1; ethnicity, 14; place of birth, 13; CD4þ percentage, 196; viral load, 199.
a177/203 children in the PI group were on lopinavir/ritonavir, 16 atazanavir and 10 darunavir. 187 were on 2NRTIs and 16 on 3NRTIs.
bTwenty-two were exposed to NVP-based maternal ART (other than single-dose NVP) and 1 to EFV-based maternal ART.
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In adjusted analysis, progression to virological failure
differed by regimen, being slowest for EFVþ 2NRTIs
and NNRTIþ 3NRTIs regimens and fastest for
NVPþ 2NRTIs regimens (global P< 0.001; Table 2).
Differences between regimens did not vary by age (<3
versus 3 years; P-interaction¼ 0.52), but depended on
the time on treatment (P-interaction¼ 0.03; Table 2).
Lower risk of failure with EFVþ 2NRTIs regimens
compared to NVPþ 2NRTIs regimens was mainly
observed during the first 2 years on treatment, with
Virological outcomes in children with HIV Duong et al. 2399
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only a modest difference thereafter. From 2 years
onwards, the risk was lowest for 4-drug NNRTI-based
regimens, though CIs were wide due to sparse data. The
benefit of the 4-drug NVP-based regimens remained
when children on EFVþ 3NRTIs regimens (n¼ 13)
were excluded (data not shown). Among children starting
ART since 2005, time to virological failure still differed
between regimens (global P¼ 0.04), with adjusted rate
ratio for EFVþ 2NRTIs versus NVPþ 2NRTIs regi-
mens being 0.52 (0.32–0.85), NNRTIþ 3NRTIs 0.54
(0.23–1.28) and protease inhibitor-based regimens 0.77
(0.47–1.27).
Earlier calendar years and older age (particularly10 years)
were independently associated with increased risk of
virological failure (Table 2). In addition, children exposed
to maternal ART, either with NNRTI-based regimens
[adjusted rate ratio 2.51 (1.38–4.57)] or other regimens
[2.06 (1.26–3.38)], were more likely to fail virologically
compared to those without exposure (global P< 0.001).
Results remained similar in sensitivity analyses, including
after adjusting for NRTI backbones and when restricted
to children born in the UK/Ireland without maternal
NNRTI-based ART exposure.
Discontinuation of initial regimen for toxicity
Seventy-seven (8%) of the 997 children discontinued the
initial NNRTI (27 NVP, 32 EFV) or protease inhibitor
(18) drug for toxicity. At 6 months, the cumulative
incidence of toxicity-related treatment discontinuation
was 4.6% (95% CI 2.8–7.1%) for NVP-based regimens,
which is higher than that observed with EFV (2.4%, 95%
CI 1.2–4.2) or protease inhibitor-based regimens (1.5%,
95% CI 0.4–4.1%; P¼ 0.09) (Fig. 3). Thereafter,
treatment discontinuation for toxicity occurred less
2400 AIDS 2014, Vol 28 No 16
Table 2. Factors at antiretroviral therapy initiation associated with virological suppression below 400copies/ml by 12 months and virological
failure during study follow-up.
Factora
Suppression by 12 months Virological failure during follow-up
Adjusted RR (95% CI) P value Adjusted RR (95% CI) P value
Type of first-line ART regimen
All children
NVPþ2NRTIs 1 0.10 1 <0.001
EFVþ2NRTIs 1.16 (0.95–1.41) 0.54 (0.40–0.72)
Boosted PI 0.92 (0.74–1.15) 0.71 (0.50–1.00)
NNRTIþ3NRTIs 1.03 (0.79–1.36) 0.63 (0.41–0.97)
Comparing regimen, by time from ART initiation
During first 2 years
NVPþ2NRTIs 1
EFVþ2NRTIs 0.46 (0.32–0.66)
Boosted PI 0.78 (0.51–1.17)
NNRTIþ3NRTIs 0.66 (0.40–1.07)
From 2 years onwards
NVPþ2NRTIs 1
EFVþ2NRTIs 0.86 (0.57–1.31)
Boosted PI 0.74 (0.43–1.26)
NNRTIþ3NRTIs 0.51 (0.28–0.92)
P for interaction between regimen
and time from initiation ¼ 0.03
Other factorsb
Calendar year of ART initiation
Before 2002 0.61 (0.47–0.79) 0.001 2.54 (1.75–3.68) <0.001
2002–2004 0.86 (0.71–1.04) 1.46 (1.04–2.04)
2005–2007 0.85 (0.70–1.01) 1.03 (0.73–1.46)
2008–2013 1 1
Age at ART initiation (years)
<1 0.61 (0.47–0.80) <0.001 0.72 (0.48–1.06) <0.001
1–2 0.72 (0.55–0.94) 0.59 (0.39–0.89)
3–4 0.93 (0.73–1.18) 0.79 (0.55–1.15)
5–9 1 1
10 1.05 (0.88–1.24) 1.68 (1.26–2.24)
Viral load at ART initiation
Per log10 increase 0.88 (0.81–0.95) 0.001
Maternal ART during pregnancy/at delivery
No 1 <0.001
NVP-based regimen 2.51 (1.38–4.57)
Other ART 2.06 (1.26–3.38)
ART, antiretroviral therapy; CI, confidence interval; EFV, efavirenz; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside
reverse transcriptase inhibitor; NVP, nevirapine; RR, rate ratio.
aResults are only presented for factors with P value less than 0.05 associated with each outcome. Both models were adjusted for a priori
confounders (previously described in the Methods section) and other predictors, with corresponding P value was less than 0.05.
bThe effect of a given factor was estimated based on data from all children combined.
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frequently for NVP-based regimens than for both EFV
and protease inhibitor-based regimens (P¼ 0.006).
By 5 years, the cumulative incidence was 6.1% (95%
CI 3.9–8.9%) for NVP, 8.3% (5.6–11.6%) for EFV and
9.8% (5.7–15.3%) for protease inhibitor-based regimens
(P¼ 0.48).
Discussion
Among HIV-infected children in the UK and Ireland,
rates of viral load suppression by 12 months were similarly
high for different first-line regimens, whereas time to
virological failure varied by regimen. Three-drug NVP-
based regimens were associated with faster progression to
failure than EFV-based regimens, mainly during the first 2
years on therapy, but similar thereafter. Four-drug
NNRTI-based regimens (89% with NVP) had the lowest
risk of failure in the longer term, though CIs were wide.
There was a moderate benefit for the three-drug protease
inhibitor over the NVP-based regimens, but this was
offset by toxicity-related treatment discontinuation
occurring more frequently for protease inhibitors with
longer time on therapy.
Our study has several important limitations. Firstly,
unmeasured confounders relating to regimen choice
could have distorted findings. Boosted protease inhibitor
regimens are preferred to NNRTI regimens for patients
perceived by clinicians to be poor adherers. Also, children
with underlying neurocognitive/psychological con-
ditions (and therefore potentially poorer adherers) are
less likely to be prescribed EFV [22]. Secondly, this is a
historical cohort (6% started ART before 2000), although
differences between regimens persisted among children
initiating since 2005. In relation to this, only a small
proportion of the children received tenofo-
virþ emtricitabine, the preferred first-line NRTI com-
bination in adolescents and adults, but used with caution
in children because of concerns about long-term bone
toxicity [4,26]. Thirdly, the choice of NRTI backbone,
which can impact on treatment efficacy, varied substan-
tially with the regimen type [16,27–30], with 76, 70 and
30% of the children on three-drug EFV, protease inhibitor
and NVP-based regimens, respectively, receiving either
lamivudineþ abacavir or tenofovirþ emtricitabine; these
combinations are generally more potent compared to
zidovudineþ lamivudine (the most commonly pre-
scribed backbone with NVP), including marginally so
among children in the recently reported CHAPAS-3 trial
(DM Gibb, personal communication). Whereas results
remained similar after adjustment for NRTI backbones, it
may have been difficult to disentangle regimen type and
individual drug effects. Finally, differences between
regimen type may vary by NRTI backbone, though
our study did not have sufficient power to evaluate this
[31].
Despite WHO recommendations of LPV/r-based regi-
mens for children under 3 years and EFV-based for 3 years
and over, most children worldwide currently initiate on
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Fig. 3. Time to discontinuation of initial non-nucleoside reverse transcriptase inhibitor or protease inhibitor for toxicity.
Children on 2 and 3 NRTIs were combined within each regimen group. Estimated cumulative incidence presented up to 7 years
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transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; NVP, nevirapine; PI, protease inhibitor.
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NVP-based regimens due to the low cost of NVP and its
wide availability in paediatric fixed-dose combination
tablets [4,32]. LPV/r is only available for young children
as a liquid which is unpalatable and has cold-chain
requirements, making it much more challenging to use
[33]. NVP also has a well characterized toxicity profile
(which is low in young children), whereas long-term
safety data for EFV (including central nervous system side
effects) and LPV/r are more limited in children [4,8]. In
our cohort, toxicity-related treatment discontinuation
was more frequent for NVP during the initial ART
period, but relatively uncommon thereafter, with higher
risks observed for other regimens in the longer term,
particularly protease inhibitors.
The decrease in the relative benefit of the three-drug EFV
over NVP-based regimens with longer time on therapy
observed in our study could partly be due to a ‘survivor
bias’ effect, as children who had not experienced early
virological failure were more likely to be good adherers.
However, a similar trend was also seen in the ARROW
trial, although interestingly, long-term virological sup-
pression was better for EFV than NVP among children
starting ART aged below 10 years, whereas the opposite
was true at age at least 10 years (AS Walker, personal
communication); neuropsychological side effects of EFV
among older children may play a part [34].
Four-drug induction with NNRTIþ 3NRTIs, decreas-
ing after 36 weeks to three drugs, improved short-term
response in the ARROW trial and our findings suggest
long-term benefit of four-drug regimens (predominantly
with NVP), as previously observed in the EPPICC infants
study [8,9,35]. However, the number of children on
EFVþ 3NRTIs regimens was too small (n¼ 13) to allow
direct comparison of the four-drug vs. the three-drug
EFV-based regimens. Four-drug NNRTI-based regi-
mens were also superior to the three-drug protease
inhibitor-based regimens in the infant analysis, and
we found a trend towards this, though CIs were wide.
These results suggest that NNRTIþ 3NRTIs long-term
‘induction maintenance’, which preserves protease
inhibitor-based therapy for the second-line treatment,
may be an alternative option, especially when ART is
initiated during infancy or early childhood when viral
load levels are particularly high and LPV/r more
challenging for use than NVP [36].
The IMPACT 1060 trial found inferior response for
the three-drug NVP versus LPV/r-based regimens by
24 weeks, with virological failure accounting for a greater
proportion of the primary endpoints in the NVP than in
the LPV/r group, irrespective of pMTCT exposure to
NVP [5,6]. Consistent with this, we observed a
moderately lower risk of virological failure for the
three-drug protease inhibitor compared to the three-drug
NVP-based regimens during the longer-term follow-up.
In contrast, the EPPICC infants study and PENPACT-1
trial reported similar virological outcomes between the
three-drugNNRTI and the protease inhibitor regimens at
12months and 4 years, respectively [7,9]. In PENPACT-1,
the initial regimen within randomized groups was chosen
by the treating clinician, with LPV/r and nelfinavir (no
longer recommended as sub-optimal) equally prescribed in
the protease inhibitor group and approximately 60 and 40%
of the NNRTI group on EFV and NVP, respectively;
however, this is unlikely to account for the trial’s findings
given that virological suppression was similar across initial
protease inhibitors and NNRTIs, Of note, long-term
virological outcome was comparable between infants on
LPV/rþ zidovudineþ lamivudine in the Children with
HIV Early antiretroviral (CHER) trial and children on
NVPþ abacavirþ lamivudine in the ARROW trial (for
both age <3 and 3 years), with 84% suppressing below
400 copies/ml in both studies at 144 weeks and at 5 years,
respectively [8,37].
Several factors may explain the increased risk of
virological failure associated with the three-drug NVP
compared to the EFV and LPV/r-based regimens
observed in our study. Firstly, drug discontinuation for
toxicity was higher for NVP during the initial period on
ART; adverse drug events may lead to poor adherence
and failure of viral load suppression [38]. In keeping with
this, the difference in risk of virological failure between
NVP and EFV was mainly observed within the first
2 years on ART in our study (and was apparent even
during the first 12 months with children on NVP more
likely to fail early following viral load suppression, data
not shown). Secondly, under-dosing of NVP in children
may play a role. The CHAPAS-1 trial in Uganda showed
the lead-in dosing for NVP (half-target dose during the
initial 2 weeks) lowers NVP levels at 4 weeks, especially in
younger children who metabolize NVP faster, potentially
increasing risk of NNRTI resistance and virological
failure [39]. Also, under-dosing was more common for
NVP than EFVamong children in the UK/Ireland before
2007 because initial US Food and Drug Administration
(FDA) paediatric dosing recommendation for NVP based
on weight was too low [40]. Thirdly, NVP has a lower
genetic barrier to resistance than LPV/r [2,34]; in the
P1060 study, initial NVP dosing was low and over half of
the children in the NVP group with virological failure
had NVP resistance at the time of failure [6]. Finally, EFV
has once-daily dosing, which may be advantageous to
adherence than twice-daily dosing for NVP. Whereas
NVP resistance after exposure to failed pMTCT ART
may lead to impaired virological response in subsequent
NVP-based treatment in children, this is unlikely to have
an important impact on our findings for various reasons
[23,41]: few children were reported to have been exposed
to single-dose NVP, maternal ART exposure had been
adjusted for in analyses, and in addition, results remained
similar when only children born in the UK/Ireland
without maternal NNRTI-based ART exposure were
included in sensitivity analyses.
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Consistent with other European findings, we observed
risk of virological failure was higher when ART was
started during adolescence, with little age effect among
younger children [3]. Poorer response in young adults
compared to older adults has been reported, likely due to
adherence issues [42]. We also found children exposed to
maternal ARTwere more likely to experience virological
failure, though the study had insufficient power to
evaluate this in more depth. Given single-dose NVP
exposure was uncommon in our cohort; this association
(also reported in previous studies) could reflect a worse
HIV prognosis among children who become HIV-
infected despite maternal ART [9,11].
In conclusion, whereas there are complexities associated
with comparing studies of children starting treatment
across different ages, calendar years and regions,
observational cohort data allow the effectiveness of
different regimens within real-life clinical settings to be
evaluated. Improved understanding of the reasons why
three-drug NVP-based regimens are associated with
higher risk of virological failure, including management-
related and/or dosing issues, could help optimize the
therapeutic effect of NVP. Nevertheless, with worldwide
ART coverage lagging significantly in children compared
to adults (34 vs. 64% in 2012) and the majority of children
worldwide currently initiating NVP-based regimens,
NVP remains an important treatment option for children
[4,32]. Furthermore, it may have a better toxicity profile
than EFV and LPV/r with longer time on therapy. For
children with viraemia controlled on NVP-based ART,
there is no strong case for changing to EFV, given the two
NNRTIs are similarly effective after 2 years on ART.
Four-drug NVP-based regimens may also be a good
alternative to protease inhibitor-based three-drug ART in
young children. The availability of more potent drugs,
including integrase inhibitors, and once-daily protease
inhibitors for adolescents offering low pill burden
regimens could improve viral load suppression in children
further in future [22,43].
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